The USFDA has approved Genzyme Corporation (Nasdaq: GENZ)’s fill/finishing, packaging and labeling of Thymoglobulin® (anti-thymocyte globulin, rabbit) at its state-of-the-art Waterford, Ireland facility.
This approval allows Genzyme to commence the manufacturing and distribution of Thymoglobulin, Genzyme Corp.’s product for the treatment of acute rejection in patients with a kidney transplant, from this single location which further enhances Genzyme's manufacturing efficiencies.
More details at Genzyme Corp.’s press release."We are very pleased with this approval, as it continues the development of our supply strategy with Waterford serving as our major European production and distribution center for large volume runs of a broad range of products," stated Mark R. Bamforth, Genzyme's senior vice president for corporate operations and pharmaceuticals.
"We look forward to also receiving similar fill/finish approvals for two of our enzyme replacement therapies at Waterford in the coming months."
.jpg)
Comment Preview